( s a cellular therapy for PD and othern...)Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's,Disease,Health

s a cellular therapy for PD and other neurodegenerative diseases;that our PLX cells could be a readily available source of important enzymes, neurotransmitters and neurotrophic factors. And that Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

Contact

Pluristem Life Systems
William Prather, 303-883-4954
Sr. VP Corporate Development
bill@pluristem.com
or
Strategic Growth International, Inc.
Richard Cooper, 212-838-1444
rcooper@sgi-ir.com
or
Segue Ventures LLC
Craig Bird, 215-885-4981
CHBird@segue.biz
or
Investors' Message Board:'"/>

Page: 1 2 3 4
Related medicine technology :

1. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
2. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
3. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
4. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
7. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
8. Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetixs AAGP
9. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
10. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
11. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage